

Lincoln Pharma earmarks Rs 30 Cr for facility expansion in Mehsana

21 September 2021 | News

The company plans to start commercial operations of Cephalosporin products in March 2022



Lincoln Pharmaceuticals plans to launch Cephalosporin products and the company has acquired a facility in Mehsana, Gujarat. There are plans to invest Rs 30 crore in the Cephalosporin plant including capacity expansion and modernisation of the facility and commercial operations is likely to start from March 2022.

The plant is expected to contribute sales of around Rs 150 crore in the next three years and will cater to all the Cephalosporin products i.e. tablet, capsule, dry syrup and injectable.

The company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021 and plans to manufacture 20 plus Cephalosporin products.

Cephalosporin is a bactericidal, broad-spectrum, and β -lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.

Mahendra Patel, MD, Lincoln Pharmaceuticals, said, "The entire expansion for Cephalosporin products will be funded from internal accruals."

Lincoln Pharma plans to manufacture 20 plus Cephalosporin products including Cefalexin Oral Suspension BP, Clavulanate Tablets, Cefixime Capsules, Cefuroxime Axetil Tablets among others. The company also looks to export in African, Latin America and Southeast Asia markets and expand to other markets after necessary approvals.